Coronado Research Welcomes Stephen Ralston as EVP of Market Access and HEOR

In a significant move to strengthen its strategic capabilities, Coronado Research has announced the appointment of Stephen Ralston as Executive Vice President of Market Access and Health Economics Outcomes Research (HEOR). With an impressive background spanning over 25 years in the pharmaceutical, biotechnology, and medical device sectors, Ralston's experience includes leadership roles at notable companies such as Genesis Research Group, Takeda, and Merck Serono. His extensive expertise positions him as a highly regarded thought leader in the realm of Market Access and HEOR.

Ralston's Expertise and Vision

Stephen Ralston is not new to the world of strategic Market Access and HEOR solutions. His career reflects a dedication to improving access to innovative therapies, having been pivotal in establishing new treatments across various critical therapy areas, including oncology, rare diseases, and immunology. Ralston's extensive experience also includes leading his consultancy in Market Access and HEOR, which complements his roles in larger pharmaceutical firms.

At Coronado Research, Ralston will leverage his vast knowledge and skills to assist clients in navigating the complexities of the healthcare landscape while ensuring the delivery of impactful solutions. "I look forward to working with our talented team to guide our customers through the intricacies of market access and HEOR strategies," Ralston commented.

A Strategic Addition for Coronado Research

Andrew MacGarvey, CEO of Coronado Research, expressed his enthusiasm about Ralston's joining the firm, stating, "I am delighted to bring Stephen into Coronado Research to lead our Market Access and HEOR services. His addition to our leadership team enhances our capability to support clients in improving patient access to innovative therapies." MacGarvey emphasized that Ralston’s expertise will complement existing functions within the company, bridging the significant gap between clinical development and commercial activities.

Coronado Research's Mission

Coronado Research is committed to optimizing the clinical development process for pharmaceutical, biotechnology, and medical device companies. The consultancy-led organization aims to harness advanced technologies, including artificial intelligence and machine learning, to maximize the value derived from available data. Their comprehensive services cover regulatory strategy, advanced analytics, market access, and health economics.

By joining various disciplines under one umbrella, Coronado Research seeks to ensure that therapies are developed with a patient-centric approach, ultimately aligning treatments with market needs and enhancing overall healthcare outcomes.

Conclusion

With Stephen Ralston at the helm of the Market Access and HEOR division, Coronado Research is poised for significant growth and success in guiding healthcare companies through the challenging landscape of drug access and economic evaluation. His wealth of experience and strategic insight will undoubtedly contribute to better patient outcomes through improved access to vital therapies on a global scale.